CompletedNot Applicable

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Sweden166 participantsStarted 2020-03-06

Plain-language summary

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * laboratory confirmed positive test for SARS-CoV-2 * admitted to ICU because of critical illness due to covid-19 Exclusion Criteria: * patients with treatment for thromboembolic complications at arrival to the ICU * short ICU length of stay defined as discharged the same or the following day as ICU admission

What they're measuring

28-days ICU mortality

Timeframe: 28 days from ICU-admission

Trial details

NCT IDNCT04412304

SponsorKarolinska Institutet

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-30

View on ClinicalTrials.gov More Covid-19 trials